Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.
Absolute Event Rate: 0% vs 0%
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Solomon et al. (Sat,) reported a other. Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: